Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun Pharma Gets USFDA Nod for Breast Cancer Drug

Sun Pharmaceutical Industries announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZ (docetaxel) for two quantity injection bottle, 20 mg/vial and 80 mg/vial. This NDA provides for the use of DOCEFREZ (docetaxel) for injection, for locally advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone refractory metastatic prostate cancer.